Clinical validation of whole-genome and transcriptome sequencing for genetic diagnostics in adult and pediatric AML

Diagnosis and risk stratification of acute myeloid leukemia (AML) rely on the detection of diverse genetic aberrations using multiple standard-of-care (SoC) assays. With the increasing number of clinically relevant alterations and limited resolution of SoC methods, whole-genome and transcriptome sequencing (WGTS) represents a promising alternative. In this multi-center study, we evaluated the technical feasibility and clinical performance of WGTS across five sites in Sweden by comparison with SoC diagnostics. A total of 235 patients (197 adults and 38 children) underwent parallel SoC testing and WGTS analysis. WGTS identified 57/58 (98%) clinically relevant gene rearrangements detected by SoC and revealed an additional 12 rearrangements, including RUNX1::RUNX1T1, KMT2A and NUP98 rearrangements. For structural variants and copy-number variants, WGS showed 90% concordance with SoC, with discrepancies mainly involving subclonal events or tetraploidy. For gene mutations, WGS achieved 94% sensitivity, detecting all NPM1, CEBPA bZIP, and IDH1/2 mutations, but missing low-frequency FLT3-ITDs. Tumor-only analysis performed comparably to paired analysis for clinically relevant variants. Diagnostic classification was highly concordant between WGTS and SoC (WHO: 94%; ICC: 93%), with improved genetic subclassification in 5 - 6% of cases by WGTS. ELN risk stratification was concordant in 97% with WGTS reclassifying 2% of patients. Finally, a ring trial involving seven cases demonstrated complete agreement across sites in identifying aberrations. In conclusion, WGTS is a feasible and accurate comprehensive diagnostic approach for AML in a decentralized setting, improving detection of clinically relevant aberrations. However, complementary high-sensitivity assays for FLT3-ITD remain necessary for routine clinical implementation.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-18
DOI
https://doi.org/10.64898/2026.11.16.26367955
Primary Topic
Acute Myeloid Leukemia Research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Clinical validation of whole-genome and transcriptome sequencing for genetic diagnostics in adult and pediatric AML

Martin Höglund, Gustav Orrsjö, Martin Jädersten, Richard Rosenquist et al.
6 links
medRxiv
Acute Myeloid Leukemia Research
preprint

Clinical validation of whole-genome and transcriptome sequencing for genetic diagnostics in adult and pediatric AML

Martin Höglund, Gustav Orrsjö, Martin Jädersten, Richard Rosenquist, Linda Fogelstrand, Panagiotis Baliakas, Thoas Fioretos, Lucia B. Cavelier, Khurram Maqbool, Sailendra Pradhananga, Stefan Deneberg, Ulrika Norén‐Nyström, Tatjana Pandzic, Lars Palmqvist, Jonas Abrahamsson, Linda Olsson, Cornelis Jan Pronk, Hartmut Vogt, Mathias Johansson, Leonie Saft, Nina Hollfelder, Christina Orsmark‐Pietras, Aleksandra Krstić, Vladimir Lazarević, Valtteri Wirta, Anna Robelius, Anna Staffas, Irina Golovleva, Kajsa Olde, Gisela Barbany, Josefin Palle, Karin Belander-Strålin
preprint en

Abstract

Diagnosis and risk stratification of acute myeloid leukemia (AML) rely on the detection of diverse genetic aberrations using multiple standard-of-care (SoC) assays. With the increasing number of clinically relevant alterations and limited resolution of SoC methods, whole-genome and transcriptome sequencing (WGTS) represents a promising alternative. In this multi-center study, we evaluated the technical feasibility and clinical performance of WGTS across five sites in Sweden by comparison with SoC diagnostics. A total of 235 patients (197 adults and 38 children) underwent parallel SoC testing and WGTS analysis. WGTS identified 57/58 (98%) clinically relevant gene rearrangements detected by SoC and revealed an additional 12 rearrangements, including RUNX1::RUNX1T1, KMT2A and NUP98 rearrangements. For structural variants and copy-number variants, WGS showed 90% concordance with SoC, with discrepancies mainly involving subclonal events or tetraploidy. For gene mutations, WGS achieved 94% sensitivity, detecting all NPM1, CEBPA bZIP, and IDH1/2 mutations, but missing low-frequency FLT3-ITDs. Tumor-only analysis performed comparably to paired analysis for clinically relevant variants. Diagnostic classification was highly concordant between WGTS and SoC (WHO: 94%; ICC: 93%), with improved genetic subclassification in 5 - 6% of cases by WGTS. ELN risk stratification was concordant in 97% with WGTS reclassifying 2% of patients. Finally, a ring trial involving seven cases demonstrated complete agreement across sites in identifying aberrations. In conclusion, WGTS is a feasible and accurate comprehensive diagnostic approach for AML in a decentralized setting, improving detection of clinically relevant aberrations. However, complementary high-sensitivity assays for FLT3-ITD remain necessary for routine clinical implementation.

medRxiv
Linköping University (SE), Uppsala University (SE), Karolinska University Hospital (SE), Uppsala University Hospital (SE), Lund University (SE), Science for Life Laboratory (SE), Sahlgrenska University Hospital (SE), Karolinska Institutet (SE), Department of Medical Sciences (RU), Skåne University Hospital (SE), Region Östergötland (SE), University of Gothenburg (SE), Umeå University (SE)
Västra Götalandsregionen, Umeå Universitet, Socialdepartementet, Akademiska Sjukhuset, Sahlgrenska Universitetssjukhuset, Science for Life Laboratory, Skånes universitetssjukhus
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon